Latest Headlines

Latest Headlines

Breast cancer-vaccine developer bags Teva Pharma, Dx deals to bolster PhIII program

The Oregon biotech revealed a pair of agreements focused on the company's therapeutic vaccine for breast cancer, a therapy in Phase III development, including a "signature" pact with the global group Teva Pharmaceutical Industries to commercialize the biotech's lead product in Israel.

Galena stock jumps with NeuVax patent

Galena Bipharma's stock jumped a cool 35% when the company received a patent granting its breast cancer vaccine exclusivity until 2028.

Late-stage Galena vax offers hope for breast cancer patients

Oregon's Galena Biopharma ($GALE) is edging closer to a submission for NeuVax after the initiation of a Phase III trial for its vaccine to prevent HER2 1+ and 2+ breast cancer recurrence in the...